Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
24.53
+0.54 (2.25%)
At close: Apr 28, 2026, 4:00 PM EDT
24.15
-0.38 (-1.55%)
After-hours: Apr 28, 2026, 6:13 PM EDT
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for Ultragenyx Pharmaceutical stock have an average target of 59.95, with a low estimate of 25 and a high estimate of 105. The average target predicts an increase of 144.39% from the current stock price of 24.53.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock from 19 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 8 | 8 | 7 | 7 |
| Buy | 8 | 11 | 11 | 11 | 10 | 10 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 19 | 20 | 20 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $50 → $67 | Buy | Maintains | $50 → $67 | +173.13% | Apr 16, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy → Hold Downgrades $61 → $25 | Strong Buy → Hold | Downgrades | $61 → $25 | +1.92% | Mar 24, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $120 → $74 | Buy | Maintains | $120 → $74 | +201.67% | Mar 12, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $128 → $79 | Strong Buy | Maintains | $128 → $79 | +222.05% | Feb 18, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $37 → $34 | Buy | Maintains | $37 → $34 | +38.61% | Feb 18, 2026 |
Financial Forecast
Revenue This Year
761.27M
from 673.00M
Increased by 13.12%
Revenue Next Year
1.05B
from 761.27M
Increased by 37.80%
EPS This Year
-4.61
from -5.83
EPS Next Year
-0.75
from -4.61
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 863.1M | 1.7B | ||||||
| Avg | 761.3M | 1.0B | ||||||
| Low | 597.5M | 858.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 28.2% | 125.8% | ||||||
| Avg | 13.1% | 37.8% | ||||||
| Low | -11.2% | 12.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.34 | 1.92 | ||||||
| Avg | -4.61 | -0.75 | ||||||
| Low | -5.50 | -2.76 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.